Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial - Concepedia

Concepedia

Publication | Closed Access

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial

95

Citations

18

References

2023

Year

Vanita R. Aroda, Jens Aberle, Lars Bardtrum, Erik Christiansen, Filip K. Knop, Sanaz Gabery, Sue D. Pedersen, John B. Buse

Diabetes ManagementClinical TherapeuticDiabetesPharmacologyClinical TrialsType 2PharmacotherapyPioneer PlusMedicine

References

	Year	Citations

Page 1